 id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Global Tuberculosis Report 2015</source><year>2015</year><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><fpage>204</fpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnippel</surname><given-names>K</given-names></name><name><surname>Rosen</surname><given-names>S</given-names></name><name><surname>Shearer</surname><given-names>K</given-names></name><name><surname>Martinson</surname><given-names>N</given-names></name><name><surname>Long</surname><given-names>L</given-names></name><name><surname>Sanne</surname><given-names>I</given-names></name><name><surname>Variava</surname><given-names>E</given-names></name></person-group><article-title>Costs of inpatient treatment for multi-drug-resistant tuberculosis in South Africa</article-title><source>Trop Med Int Health</source><year>2013</year><volume>18</volume><issue>1</issue><fpage>109</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1111/tmi.12018</pub-id><?supplied-pmid 23170876?><pub-id pub-id-type="pmid">23170876</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dheda</surname><given-names>K</given-names></name><name><surname>Gumbo</surname><given-names>T</given-names></name><name><surname>Gandhi</surname><given-names>NR</given-names></name><name><surname>Murray</surname><given-names>M</given-names></name><name><surname>Theron</surname><given-names>G</given-names></name><name><surname>Udwadia</surname><given-names>Z</given-names></name><name><surname>Migliori</surname><given-names>GB</given-names></name><name><surname>Warren</surname><given-names>R</given-names></name></person-group><article-title>Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis</article-title><source>Lancet Respir Med</source><year>2014</year><volume>2</volume><issue>4</issue><fpage>321</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(14)70031-1</pub-id><?supplied-pmid 24717628?><pub-id pub-id-type="pmid">24717628</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><name><surname>Parida</surname><given-names>SK</given-names></name><name><surname>Keshavjee</surname><given-names>S</given-names></name><name><surname>Cassell</surname><given-names>G</given-names></name><name><surname>Wallis</surname><given-names>R</given-names></name><name><surname>Axelsson-Robertsson</surname><given-names>R</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Andersson</surname><given-names>J</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name></person-group><article-title>Inflammation and tuberculosis: host-directed therapies</article-title><source>J Intern Med</source><year>2015</year><volume>277</volume><issue>4</issue><fpage>373</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1111/joim.12256</pub-id><?supplied-pmid 24717092?><pub-id pub-id-type="pmid">24717092</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>RP</given-names></name><name><surname>Meintjes</surname><given-names>G</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name></person-group><article-title>HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome</article-title><source>Semin Immunopathol</source><year>2015</year><?supplied-pmid 26423994?><pub-id pub-id-type="pmid">26423994</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravimohan</surname><given-names>S</given-names></name><name><surname>Tamuhla</surname><given-names>N</given-names></name><name><surname>Steenhoff</surname><given-names>AP</given-names></name><name><surname>Letlhogile</surname><given-names>R</given-names></name><name><surname>Nfanyana</surname><given-names>K</given-names></name><name><surname>Bellamy</surname><given-names>SL</given-names></name><name><surname>MacGregor</surname><given-names>RR</given-names></name><name><surname>Gross</surname><given-names>R</given-names></name><name><surname>Weissman</surname><given-names>D</given-names></name><name><surname>Bisson</surname><given-names>GP</given-names></name></person-group><article-title>Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study</article-title><source>Lancet Infect Dis</source><year>2015</year><?supplied-pmid 25672566?><pub-id pub-id-type="pmid">25672566</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><name><surname>Parida</surname><given-names>SK</given-names></name><name><surname>Keshavjee</surname><given-names>S</given-names></name><name><surname>Cassell</surname><given-names>G</given-names></name><name><surname>Wallis</surname><given-names>R</given-names></name><name><surname>Axelsson-Robertsson</surname><given-names>R</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Andersson</surname><given-names>J</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name></person-group><article-title>Inflammation and tuberculosis: host-directed therapies</article-title><source>J Intern Med</source><year>2014</year></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meintjes</surname><given-names>G</given-names></name><name><surname>Rangaka</surname><given-names>MX</given-names></name><name><surname>Maartens</surname><given-names>G</given-names></name><name><surname>Rebe</surname><given-names>K</given-names></name><name><surname>Morroni</surname><given-names>C</given-names></name><name><surname>Pepper</surname><given-names>DJ</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name></person-group><article-title>Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><issue>5</issue><fpage>667</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1086/596764</pub-id><?supplied-pmid 19191655?><pub-id pub-id-type="pmid">19191655</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasipanodya</surname><given-names>JG</given-names></name><name><surname>McNabb</surname><given-names>SJ</given-names></name><name><surname>Hilsenrath</surname><given-names>P</given-names></name><name><surname>Bae</surname><given-names>S</given-names></name><name><surname>Lykens</surname><given-names>K</given-names></name><name><surname>Vecino</surname><given-names>E</given-names></name><name><surname>Munguia</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>TL</given-names></name><name><surname>Drewyer</surname><given-names>G</given-names></name><name><surname>Weis</surname><given-names>SE</given-names></name></person-group><article-title>Pulmonary impairment after tuberculosis and its contribution to TB burden</article-title><source>BMC Public Health</source><year>2010</year><volume>10</volume><fpage>259</fpage><pub-id pub-id-type="doi">10.1186/1471-2458-10-259</pub-id><?supplied-pmid 20482835?><pub-id pub-id-type="pmid">20482835</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Chakaya</surname><given-names>J</given-names></name><name><surname>Centis</surname><given-names>R</given-names></name><name><surname>D'Ambrosio</surname><given-names>L</given-names></name><name><surname>Mwaba</surname><given-names>P</given-names></name><name><surname>Bates</surname><given-names>M</given-names></name><name><surname>Kapata</surname><given-names>N</given-names></name><name><surname>Nyirenda</surname><given-names>T</given-names></name><name><surname>Chanda</surname><given-names>D</given-names></name><name><surname>Mfinanga</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies</article-title><source>Lancet Respir Med</source><year>2015</year><volume>3</volume><issue>3</issue><fpage>220</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(15)00063-6</pub-id><?supplied-pmid 25773212?><pub-id pub-id-type="pmid">25773212</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinho</surname><given-names>ST</given-names></name><name><surname>Rodrigues</surname><given-names>P</given-names></name><name><surname>Andrade</surname><given-names>RF</given-names></name><name><surname>Serra</surname><given-names>H</given-names></name><name><surname>Lopes</surname><given-names>JS</given-names></name><name><surname>Gomes</surname><given-names>MG</given-names></name></person-group><article-title>Impact of tuberculosis treatment length and adherence under different transmission intensities</article-title><source>Theor Popul Biol</source><year>2015</year><volume>104</volume><fpage>68</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1016/j.tpb.2015.06.004</pub-id><?supplied-pmid 26163050?><pub-id pub-id-type="pmid">26163050</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoger</surname><given-names>S</given-names></name><name><surname>Lykens</surname><given-names>K</given-names></name><name><surname>Beavers</surname><given-names>SF</given-names></name><name><surname>Katz</surname><given-names>D</given-names></name><name><surname>Miller</surname><given-names>TL</given-names></name></person-group><article-title>Longevity loss among cured tuberculosis patients and the potential value of prevention</article-title><source>Int J Tuberc Lung Dis</source><year>2014</year><volume>18</volume><issue>11</issue><fpage>1347</fpage><lpage>1352</lpage><pub-id pub-id-type="doi">10.5588/ijtld.14.0242</pub-id><?supplied-pmid 25299869?><pub-id pub-id-type="pmid">25299869</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>SH</given-names></name><name><surname>Lange</surname><given-names>C</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><name><surname>Balaji</surname><given-names>KN</given-names></name><name><surname>Lotze</surname><given-names>M</given-names></name><name><surname>Schito</surname><given-names>M</given-names></name><name><surname>Zumla</surname><given-names>AI</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name></person-group><article-title>Progress in tuberculosis vaccine development and host-directed therapies--a state of the art review</article-title><source>Lancet Respir Med</source><year>2014</year><volume>2</volume><issue>4</issue><fpage>301</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(14)70033-5</pub-id><?supplied-pmid 24717627?><pub-id pub-id-type="pmid">24717627</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>RK</given-names></name><name><surname>Rohava</surname><given-names>Z</given-names></name><name><surname>Balaji</surname><given-names>KN</given-names></name><name><surname>Hoffner</surname><given-names>SE</given-names></name><name><surname>Gaines</surname><given-names>H</given-names></name><name><surname>Magalhaes</surname><given-names>I</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Skrahina</surname><given-names>A</given-names></name><name><surname>Maeurer</surname><given-names>MJ</given-names></name></person-group><article-title>Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus</article-title><source>BMC Infect Dis</source><year>2012</year><volume>12</volume><issue>1</issue><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/1471-2334-12-41</pub-id><?supplied-pmid 22336002?><pub-id pub-id-type="pmid">22336002</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>MP</given-names></name><name><surname>Graham</surname><given-names>CM</given-names></name><name><surname>McNab</surname><given-names>FW</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Bloch</surname><given-names>SA</given-names></name><name><surname>Oni</surname><given-names>T</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Banchereau</surname><given-names>R</given-names></name><name><surname>Skinner</surname><given-names>J</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis</article-title><source>Nature</source><year>2010</year><volume>466</volume><issue>7309</issue><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/nature09247</pub-id><?supplied-pmid 20725040?><pub-id pub-id-type="pmid">20725040</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>RS</given-names></name><name><surname>Kim</surname><given-names>P</given-names></name><name><surname>Cole</surname><given-names>S</given-names></name><name><surname>Hanna</surname><given-names>D</given-names></name><name><surname>Andrade</surname><given-names>BB</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name><name><surname>Schito</surname><given-names>M</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name></person-group><article-title>Tuberculosis biomarkers discovery: developments, needs, and challenges</article-title><source>Lancet Infect Dis</source><year>2013</year><volume>13</volume><issue>4</issue><fpage>362</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(13)70034-3</pub-id><?supplied-pmid 23531389?><pub-id pub-id-type="pmid">23531389</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>AI</given-names></name><name><surname>Schito</surname><given-names>M</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name></person-group><article-title>Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccines</article-title><source>Lancet Infect Dis</source><year>2014</year><volume>14</volume><issue>4</issue><fpage>267</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(14)70028-3</pub-id><?supplied-pmid 24670623?><pub-id pub-id-type="pmid">24670623</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahon</surname><given-names>RN</given-names></name><name><surname>Hafner</surname><given-names>R</given-names></name></person-group><article-title>Immune Cell Regulatory Pathways Unexplored as Host-Directed Therapeutic Targets for Mycobacterium tuberculosis: An Opportunity to Apply Precision Medicine Innovations to Infectious Diseases</article-title><source>Clin Infect Dis</source><year>2015</year><volume>61</volume><issue>suppl 3</issue><fpage>S200</fpage><lpage>S216</lpage><pub-id pub-id-type="doi">10.1093/cid/civ621</pub-id><?supplied-pmid 26409283?><pub-id pub-id-type="pmid">26409283</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Chakaya</surname><given-names>J</given-names></name><name><surname>Hoelscher</surname><given-names>M</given-names></name><name><surname>Ntoumi</surname><given-names>F</given-names></name><name><surname>Rustomjee</surname><given-names>R</given-names></name><name><surname>Vilaplana</surname><given-names>C</given-names></name><name><surname>Yeboah-Manu</surname><given-names>D</given-names></name><name><surname>Rasolof</surname><given-names>V</given-names></name><name><surname>Munderi</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><etal/></person-group><article-title>Towards host-directed therapies for tuberculosis</article-title><source>Nat Rev Drug Discov</source><year>2015</year><?supplied-pmid 26184493?><pub-id pub-id-type="pmid">26184493</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname><given-names>CA</given-names></name><name><surname>Nigro</surname><given-names>N</given-names></name><name><surname>Briel</surname><given-names>M</given-names></name><name><surname>Schuetz</surname><given-names>P</given-names></name><name><surname>Ullmer</surname><given-names>E</given-names></name><name><surname>Suter-Widmer</surname><given-names>I</given-names></name><name><surname>Winzeler</surname><given-names>B</given-names></name><name><surname>Bingisser</surname><given-names>R</given-names></name><name><surname>Elsaesser</surname><given-names>H</given-names></name><name><surname>Drozdov</surname><given-names>D</given-names></name><etal/></person-group><article-title>Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial</article-title><source>Lancet</source><year>2015</year></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Remmelts</surname><given-names>HH</given-names></name><name><surname>Meijvis</surname><given-names>SC</given-names></name><name><surname>Biesma</surname><given-names>DH</given-names></name><name><surname>van Velzen-Blad</surname><given-names>H</given-names></name><name><surname>Voorn</surname><given-names>GP</given-names></name><name><surname>Grutters</surname><given-names>JC</given-names></name><name><surname>Bos</surname><given-names>WJ</given-names></name><name><surname>Rijkers</surname><given-names>GT</given-names></name></person-group><article-title>Dexamethasone downregulates the systemic cytokine response in patients with community-acquired pneumonia</article-title><source>Clin Vaccine Immunol</source><year>2012</year><volume>19</volume><issue>9</issue><fpage>1532</fpage><lpage>1538</lpage><pub-id pub-id-type="doi">10.1128/CVI.00423-12</pub-id><?supplied-pmid 22855392?><pub-id pub-id-type="pmid">22855392</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muthuswamy</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>TC</given-names></name><name><surname>Carasso</surname><given-names>B</given-names></name><name><surname>Antonio</surname><given-names>M</given-names></name><name><surname>Dandamudi</surname><given-names>N</given-names></name></person-group><article-title>Prednisone as adjunctive therapy in the management of pulmonary tuberculosis. Report of 12 cases and review of the literature</article-title><source>Chest</source><year>1995</year><volume>107</volume><issue>6</issue><fpage>1621</fpage><lpage>1630</lpage><pub-id pub-id-type="doi">10.1378/chest.107.6.1621</pub-id><?supplied-pmid 7781357?><pub-id pub-id-type="pmid">7781357</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>DM</given-names></name><name><surname>Ramakrishnan</surname><given-names>L</given-names></name></person-group><article-title>TB: the Yin and Yang of lipid mediators</article-title><source>Curr Opin Pharmacol</source><year>2013</year><volume>13</volume><issue>4</issue><fpage>641</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2013.06.007</pub-id><?supplied-pmid 23849093?><pub-id pub-id-type="pmid">23849093</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zelasko</surname><given-names>S</given-names></name><name><surname>Arnold</surname><given-names>WR</given-names></name><name><surname>Das</surname><given-names>A</given-names></name></person-group><article-title>Endocannabinoid metabolism by cytochrome P450 monooxygenases</article-title><source>Prostaglandins Other Lipid Mediat</source><year>2014</year><?supplied-pmid 25461979?><pub-id pub-id-type="pmid">25461979</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Reddy</surname><given-names>GV</given-names></name><name><surname>Reddanna</surname><given-names>P</given-names></name></person-group><article-title>Eicosanoids in inflammation and cancer: the role of COX-2</article-title><source>Expert Rev Clin Immunol</source><year>2009</year><volume>5</volume><issue>2</issue><fpage>145</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1586/1744666X.5.2.145</pub-id><?supplied-pmid 20477063?><pub-id pub-id-type="pmid">20477063</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>DM</given-names></name><name><surname>Roca</surname><given-names>FJ</given-names></name><name><surname>Oh</surname><given-names>SF</given-names></name><name><surname>McFarland</surname><given-names>R</given-names></name><name><surname>Vickery</surname><given-names>TW</given-names></name><name><surname>Ray</surname><given-names>JP</given-names></name><name><surname>Ko</surname><given-names>DC</given-names></name><name><surname>Zou</surname><given-names>Y</given-names></name><name><surname>Bang</surname><given-names>ND</given-names></name><name><surname>Chau</surname><given-names>TT</given-names></name><etal/></person-group><article-title>Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections</article-title><source>Cell</source><year>2012</year><volume>148</volume><issue>3</issue><fpage>434</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.12.023</pub-id><?supplied-pmid 22304914?><pub-id pub-id-type="pmid">22304914</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilaplana</surname><given-names>C</given-names></name><name><surname>Marzo</surname><given-names>E</given-names></name><name><surname>Tapia</surname><given-names>G</given-names></name><name><surname>Diaz</surname><given-names>J</given-names></name><name><surname>Garcia</surname><given-names>V</given-names></name><name><surname>Cardona</surname><given-names>PJ</given-names></name></person-group><article-title>Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis</article-title><source>J Infect Dis</source><year>2013</year><volume>208</volume><issue>2</issue><fpage>199</fpage><lpage>202</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit152</pub-id><?supplied-pmid 23564636?><pub-id pub-id-type="pmid">23564636</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Guzman JD, Evangelopoulos D, Gupta A, Birchall K, Mwaigwisya S, Saxty B, McHugh TD, Gibbons S, Malkinson J, Bhakta S. Antitubercular specific activity of ibuprofen and the other 2-arylpropanoic acids using the HT-SPOTi whole-cell phenotypic assay. BMJ Open. 2013;3(6). doi:10.1136/bmjopen-2013-002672.</mixed-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>W</given-names></name><name><surname>De Chandt</surname><given-names>MT</given-names></name><name><surname>Cairns</surname><given-names>CB</given-names></name></person-group><article-title>Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease</article-title><source>Int J Clin Pract</source><year>2007</year><volume>61</volume><issue>4</issue><fpage>663</fpage><lpage>676</lpage><pub-id pub-id-type="doi">10.1111/j.1742-1241.2007.01320.x</pub-id><?supplied-pmid 17394438?><pub-id pub-id-type="pmid">17394438</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer-Barber</surname><given-names>KD</given-names></name><name><surname>Andrade</surname><given-names>BB</given-names></name><name><surname>Oland</surname><given-names>SD</given-names></name><name><surname>Amaral</surname><given-names>EP</given-names></name><name><surname>Barber</surname><given-names>DL</given-names></name><name><surname>Gonzales</surname><given-names>J</given-names></name><name><surname>Derrick</surname><given-names>SC</given-names></name><name><surname>Shi</surname><given-names>R</given-names></name><name><surname>Kumar</surname><given-names>NP</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><etal/></person-group><article-title>Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk</article-title><source>Nature</source><year>2014</year><volume>511</volume><issue>7507</issue><fpage>99</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1038/nature13489</pub-id><?supplied-pmid 24990750?><pub-id pub-id-type="pmid">24990750</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>MK</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name></person-group><article-title>Anti-inflammatory effects of statins: clinical evidence and basic mechanisms</article-title><source>Nat Rev Drug Discov</source><year>2005</year><volume>4</volume><issue>12</issue><fpage>977</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1038/nrd1901</pub-id><?supplied-pmid 16341063?><pub-id pub-id-type="pmid">16341063</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>B</given-names></name><name><surname>Mulhaupt</surname><given-names>F</given-names></name><name><surname>Myit</surname><given-names>S</given-names></name><name><surname>Mach</surname><given-names>F</given-names></name></person-group><article-title>Statins as a newly recognized type of immunomodulator</article-title><source>Nat Med</source><year>2000</year><volume>6</volume><issue>12</issue><fpage>1399</fpage><lpage>1402</lpage><pub-id pub-id-type="doi">10.1038/82219</pub-id><?supplied-pmid 11100127?><pub-id pub-id-type="pmid">11100127</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>RW</given-names></name><name><surname>Riis</surname><given-names>A</given-names></name><name><surname>Kornum</surname><given-names>JB</given-names></name><name><surname>Christensen</surname><given-names>S</given-names></name><name><surname>Johnsen</surname><given-names>SP</given-names></name><name><surname>Sorensen</surname><given-names>HT</given-names></name></person-group><article-title>Preadmission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients</article-title><source>Arch Intern Med</source><year>2008</year><volume>168</volume><issue>19</issue><fpage>2081</fpage><lpage>2087</lpage><pub-id pub-id-type="doi">10.1001/archinte.168.19.2081</pub-id><?supplied-pmid 18955636?><pub-id pub-id-type="pmid">18955636</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>RW</given-names></name><name><surname>Hundborg</surname><given-names>HH</given-names></name><name><surname>Johnsen</surname><given-names>SP</given-names></name><name><surname>Pedersen</surname><given-names>L</given-names></name><name><surname>Sorensen</surname><given-names>HT</given-names></name><name><surname>Schonheyder</surname><given-names>HC</given-names></name><name><surname>Lervang</surname><given-names>HH</given-names></name></person-group><article-title>Statin use and mortality within 180&#x000a0;days after bacteremia: a population-based cohort study</article-title><source>Crit Care Med</source><year>2006</year><volume>34</volume><issue>4</issue><fpage>1080</fpage><lpage>1086</lpage><pub-id pub-id-type="doi">10.1097/01.CCM.0000207345.92928.E4</pub-id><?supplied-pmid 16484926?><pub-id pub-id-type="pmid">16484926</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalmers</surname><given-names>JD</given-names></name><name><surname>Singanayagam</surname><given-names>A</given-names></name><name><surname>Murray</surname><given-names>MP</given-names></name><name><surname>Hill</surname><given-names>AT</given-names></name></person-group><article-title>Prior statin use is associated with improved outcomes in community-acquired pneumonia</article-title><source>Am J Med</source><year>2008</year><volume>121</volume><issue>11</issue><fpage>1002</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2008.06.030</pub-id><?supplied-pmid 18954848?><pub-id pub-id-type="pmid">18954848</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortensen</surname><given-names>EM</given-names></name><name><surname>Restrepo</surname><given-names>MI</given-names></name><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Pugh</surname><given-names>J</given-names></name></person-group><article-title>The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia</article-title><source>Respir Res</source><year>2005</year><volume>6</volume><fpage>82</fpage><pub-id pub-id-type="doi">10.1186/1465-9921-6-82</pub-id><?supplied-pmid 16042797?><pub-id pub-id-type="pmid">16042797</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parihar</surname><given-names>SP</given-names></name><name><surname>Guler</surname><given-names>R</given-names></name><name><surname>Khutlang</surname><given-names>R</given-names></name><name><surname>Lang</surname><given-names>DM</given-names></name><name><surname>Hurdayal</surname><given-names>R</given-names></name><name><surname>Mhlanga</surname><given-names>MM</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Marais</surname><given-names>AD</given-names></name><name><surname>Brombacher</surname><given-names>F</given-names></name></person-group><article-title>Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation</article-title><source>J Infect Dis</source><year>2014</year><volume>209</volume><issue>5</issue><fpage>754</fpage><lpage>763</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit550</pub-id><?supplied-pmid 24133190?><pub-id pub-id-type="pmid">24133190</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skerry</surname><given-names>C</given-names></name><name><surname>Pinn</surname><given-names>ML</given-names></name><name><surname>Bruiners</surname><given-names>N</given-names></name><name><surname>Pine</surname><given-names>R</given-names></name><name><surname>Gennaro</surname><given-names>ML</given-names></name><name><surname>Karakousis</surname><given-names>PC</given-names></name></person-group><article-title>Simvastatin increases the in vivo activity of the first-line tuberculosis regimen</article-title><source>J Antimicrob Chemother</source><year>2014</year><volume>69</volume><issue>9</issue><fpage>2453</fpage><lpage>2457</lpage><pub-id pub-id-type="doi">10.1093/jac/dku166</pub-id><?supplied-pmid 24855121?><pub-id pub-id-type="pmid">24855121</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>YA</given-names></name><name><surname>Choi</surname><given-names>NK</given-names></name><name><surname>Seong</surname><given-names>JM</given-names></name><name><surname>Heo</surname><given-names>EY</given-names></name><name><surname>Koo</surname><given-names>BK</given-names></name><name><surname>Hwang</surname><given-names>SS</given-names></name><name><surname>Park</surname><given-names>BJ</given-names></name><name><surname>Yim</surname><given-names>JJ</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name></person-group><article-title>The effects of statin use on the development of tuberculosis among patients with diabetes mellitus</article-title><source>Int J Tuberc Lung Dis</source><year>2014</year><volume>18</volume><issue>6</issue><fpage>717</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.5588/ijtld.13.0854</pub-id><?supplied-pmid 24903944?><pub-id pub-id-type="pmid">24903944</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foretz</surname><given-names>M</given-names></name><name><surname>Guigas</surname><given-names>B</given-names></name><name><surname>Bertrand</surname><given-names>L</given-names></name><name><surname>Pollak</surname><given-names>M</given-names></name><name><surname>Viollet</surname><given-names>B</given-names></name></person-group><article-title>Metformin: From Mechanisms of Action to Therapies</article-title><source>Cell Metab</source><year>2014</year><volume>20</volume><issue>6</issue><fpage>953</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.09.018</pub-id><?supplied-pmid 25456737?><pub-id pub-id-type="pmid">25456737</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhal</surname><given-names>A</given-names></name><name><surname>Jie</surname><given-names>L</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Hong</surname><given-names>GS</given-names></name><name><surname>Leow</surname><given-names>MK</given-names></name><name><surname>Paleja</surname><given-names>B</given-names></name><name><surname>Tsenova</surname><given-names>L</given-names></name><name><surname>Kurepina</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zolezzi</surname><given-names>F</given-names></name><etal/></person-group><article-title>Metformin as adjunct antituberculosis therapy</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><issue>263</issue><fpage>263ra159</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3009885</pub-id><?supplied-pmid 25411472?><pub-id pub-id-type="pmid">25411472</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eikawa</surname><given-names>S</given-names></name><name><surname>Nishida</surname><given-names>M</given-names></name><name><surname>Mizukami</surname><given-names>S</given-names></name><name><surname>Yamazaki</surname><given-names>C</given-names></name><name><surname>Nakayama</surname><given-names>E</given-names></name><name><surname>Udono</surname><given-names>H</given-names></name></person-group><article-title>Immune-mediated antitumor effect by type 2 diabetes drug, metformin</article-title><source>Proc Natl Acad Sci U S A</source><year>2015</year><volume>112</volume><issue>6</issue><fpage>1809</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1073/pnas.1417636112</pub-id><?supplied-pmid 25624476?><pub-id pub-id-type="pmid">25624476</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>EL</given-names></name><name><surname>Walsh</surname><given-names>MC</given-names></name><name><surname>Cejas</surname><given-names>PJ</given-names></name><name><surname>Harms</surname><given-names>GM</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>LS</given-names></name><name><surname>Jones</surname><given-names>RG</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name></person-group><article-title>Enhancing CD8 T-cell memory by modulating fatty acid metabolism</article-title><source>Nature</source><year>2009</year><volume>460</volume><issue>7251</issue><fpage>103</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1038/nature08097</pub-id><?supplied-pmid 19494812?><pub-id pub-id-type="pmid">19494812</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napier</surname><given-names>RJ</given-names></name><name><surname>Norris</surname><given-names>BA</given-names></name><name><surname>Swimm</surname><given-names>A</given-names></name><name><surname>Giver</surname><given-names>CR</given-names></name><name><surname>Harris</surname><given-names>WA</given-names></name><name><surname>Laval</surname><given-names>J</given-names></name><name><surname>Napier</surname><given-names>BA</given-names></name><name><surname>Patel</surname><given-names>G</given-names></name><name><surname>Crump</surname><given-names>R</given-names></name><name><surname>Peng</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity</article-title><source>PLoS Pathog</source><year>2015</year><volume>11</volume><issue>3</issue><fpage>e1004770</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1004770</pub-id><?supplied-pmid 25822986?><pub-id pub-id-type="pmid">25822986</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Napier</surname><given-names>RJ</given-names></name><name><surname>Rafi</surname><given-names>W</given-names></name><name><surname>Cheruvu</surname><given-names>M</given-names></name><name><surname>Powell</surname><given-names>KR</given-names></name><name><surname>Zaunbrecher</surname><given-names>MA</given-names></name><name><surname>Bornmann</surname><given-names>W</given-names></name><name><surname>Salgame</surname><given-names>P</given-names></name><name><surname>Shinnick</surname><given-names>TM</given-names></name><name><surname>Kalman</surname><given-names>D</given-names></name></person-group><article-title>Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis</article-title><source>Cell Host Microbe</source><year>2011</year><volume>10</volume><issue>5</issue><fpage>475</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2011.09.010</pub-id><?supplied-pmid 22100163?><pub-id pub-id-type="pmid">22100163</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riches</surname><given-names>JC</given-names></name><name><surname>Gribben</surname><given-names>JG</given-names></name></person-group><article-title>Immunomodulation and immune reconstitution in chronic lymphocytic leukemia</article-title><source>Semin Hematol</source><year>2014</year><volume>51</volume><issue>3</issue><fpage>228</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1053/j.seminhematol.2014.05.006</pub-id><?supplied-pmid 25048786?><pub-id pub-id-type="pmid">25048786</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boddy</surname><given-names>AV</given-names></name><name><surname>Yule</surname><given-names>SM</given-names></name></person-group><article-title>Metabolism and pharmacokinetics of oxazaphosphorines</article-title><source>Clin Pharmacokinet</source><year>2000</year><volume>38</volume><issue>4</issue><fpage>291</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.2165/00003088-200038040-00001</pub-id><?supplied-pmid 10803453?><pub-id pub-id-type="pmid">10803453</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>AG</given-names></name><name><surname>Tilby</surname><given-names>MJ</given-names></name></person-group><article-title>Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies</article-title><source>Blood Rev</source><year>1992</year><volume>6</volume><issue>3</issue><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/0268-960X(92)90028-O</pub-id><?supplied-pmid 1422285?><pub-id pub-id-type="pmid">1422285</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dimeloe</surname><given-names>S</given-names></name><name><surname>Frick</surname><given-names>C</given-names></name><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Gubser</surname><given-names>PM</given-names></name><name><surname>Razik</surname><given-names>L</given-names></name><name><surname>Bantug</surname><given-names>GR</given-names></name><name><surname>Ravon</surname><given-names>M</given-names></name><name><surname>Langenkamp</surname><given-names>A</given-names></name><name><surname>Hess</surname><given-names>C</given-names></name></person-group><article-title>Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis</article-title><source>Eur J Immunol</source><year>2014</year><volume>44</volume><issue>12</issue><fpage>3614</fpage><lpage>3620</lpage><pub-id pub-id-type="doi">10.1002/eji.201444879</pub-id><?supplied-pmid 25251877?><pub-id pub-id-type="pmid">25251877</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanakry</surname><given-names>CG</given-names></name><name><surname>Ganguly</surname><given-names>S</given-names></name><name><surname>Zahurak</surname><given-names>M</given-names></name><name><surname>Bolanos-Meade</surname><given-names>J</given-names></name><name><surname>Thoburn</surname><given-names>C</given-names></name><name><surname>Perkins</surname><given-names>B</given-names></name><name><surname>Fuchs</surname><given-names>EJ</given-names></name><name><surname>Jones</surname><given-names>RJ</given-names></name><name><surname>Hess</surname><given-names>AD</given-names></name><name><surname>Luznik</surname><given-names>L</given-names></name></person-group><article-title>Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide</article-title><source>Sci Transl Med</source><year>2013</year><volume>5</volume><issue>211</issue><fpage>211ra157</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3006960</pub-id><?supplied-pmid 24225944?><pub-id pub-id-type="pmid">24225944</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walter</surname><given-names>S</given-names></name><name><surname>Weinschenk</surname><given-names>T</given-names></name><name><surname>Stenzl</surname><given-names>A</given-names></name><name><surname>Zdrojowy</surname><given-names>R</given-names></name><name><surname>Pluzanska</surname><given-names>A</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Staehler</surname><given-names>M</given-names></name><name><surname>Brugger</surname><given-names>W</given-names></name><name><surname>Dietrich</surname><given-names>PY</given-names></name><name><surname>Mendrzyk</surname><given-names>R</given-names></name><etal/></person-group><article-title>Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival</article-title><source>Nat Med</source><year>2012</year><volume>18</volume><issue>8</issue><fpage>1254</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1038/nm.2883</pub-id><?supplied-pmid 22842478?><pub-id pub-id-type="pmid">22842478</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name></person-group><article-title>Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs</article-title><source>J Infect Dis</source><year>2012</year><volume>205</volume><issue>Suppl 2</issue><fpage>S335</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1093/infdis/jir881</pub-id><?supplied-pmid 22448017?><pub-id pub-id-type="pmid">22448017</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Xie</surname><given-names>WP</given-names></name><name><surname>Kong</surname><given-names>H</given-names></name><name><surname>Min</surname><given-names>R</given-names></name><name><surname>Hu</surname><given-names>CM</given-names></name><name><surname>Zhou</surname><given-names>XB</given-names></name><name><surname>Lu</surname><given-names>ZM</given-names></name><name><surname>Ji</surname><given-names>XH</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Enrichment of regulatory T-cells in blood of patients with multidrug-resistant tuberculosis</article-title><source>Int J Tuberc Lung Dis</source><year>2015</year><volume>19</volume><issue>10</issue><fpage>1230</fpage><lpage>1238</lpage><pub-id pub-id-type="doi">10.5588/ijtld.15.0148</pub-id><?supplied-pmid 26459539?><pub-id pub-id-type="pmid">26459539</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Dey</surname><given-names>AB</given-names></name><name><surname>Mohan</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>PK</given-names></name><name><surname>Mitra</surname><given-names>DK</given-names></name></person-group><article-title>Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-gamma producing T cells</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><issue>9</issue><fpage>e44728</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0044728</pub-id><?supplied-pmid 23028594?><pub-id pub-id-type="pmid">23028594</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>PA</given-names></name><name><surname>Richon</surname><given-names>VM</given-names></name><name><surname>Miller</surname><given-names>T</given-names></name><name><surname>Kelly</surname><given-names>WK</given-names></name></person-group><article-title>Histone deacetylase inhibitors</article-title><source>Adv Cancer Res</source><year>2004</year><volume>91</volume><fpage>137</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/S0065-230X(04)91004-4</pub-id><?supplied-pmid 15327890?><pub-id pub-id-type="pmid">15327890</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname><given-names>AA</given-names></name><name><surname>Chabner</surname><given-names>BA</given-names></name></person-group><article-title>Histone deacetylase inhibitors in cancer therapy</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><issue>32</issue><fpage>5459</fpage><lpage>5468</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.22.1291</pub-id><?supplied-pmid 19826124?><pub-id pub-id-type="pmid">19826124</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hymes</surname><given-names>KB</given-names></name></person-group><article-title>The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma</article-title><source>Clin Lymphoma Myeloma Leuk</source><year>2010</year><volume>10</volume><issue>2</issue><fpage>98</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.3816/CLML.2010.n.014</pub-id><?supplied-pmid 20371442?><pub-id pub-id-type="pmid">20371442</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duenas-Gonzalez</surname><given-names>A</given-names></name><name><surname>Candelaria</surname><given-names>M</given-names></name><name><surname>Perez-Plascencia</surname><given-names>C</given-names></name><name><surname>Perez-Cardenas</surname><given-names>E</given-names></name><name><surname>de la Cruz-Hernandez</surname><given-names>E</given-names></name><name><surname>Herrera</surname><given-names>LA</given-names></name></person-group><article-title>Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors</article-title><source>Cancer Treat Rev</source><year>2008</year><volume>34</volume><issue>3</issue><fpage>206</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2007.11.003</pub-id><?supplied-pmid 18226465?><pub-id pub-id-type="pmid">18226465</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cang</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer</article-title><source>J Hematol Oncol</source><year>2009</year><volume>2</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/1756-8722-2-22</pub-id><?supplied-pmid 19486511?><pub-id pub-id-type="pmid">19486511</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>BR</given-names></name><name><surname>You</surname><given-names>BR</given-names></name><name><surname>Park</surname><given-names>WH</given-names></name></person-group><article-title>Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis</article-title><source>Oncol Rep</source><year>2013</year></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Shao</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>FR</given-names></name><name><surname>Ng</surname><given-names>HK</given-names></name><name><surname>Chen</surname><given-names>ZP</given-names></name></person-group><article-title>Autophagy induced by valproic acid is associated with oxidative stress in glioma cell lines</article-title><source>Neuro Oncol</source><year>2010</year><volume>12</volume><issue>4</issue><fpage>328</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1093/neuonc/nop005</pub-id><?supplied-pmid 20308311?><pub-id pub-id-type="pmid">20308311</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>GR</given-names></name><name><surname>Bruckman</surname><given-names>RS</given-names></name><name><surname>Chu</surname><given-names>YL</given-names></name><name><surname>Spector</surname><given-names>SA</given-names></name></person-group><article-title>Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1</article-title><source>J Biol Chem</source><year>2015</year><volume>290</volume><issue>8</issue><fpage>5028</fpage><lpage>5040</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.605428</pub-id><?supplied-pmid 25540204?><pub-id pub-id-type="pmid">25540204</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ylisastigui</surname><given-names>L</given-names></name><name><surname>Archin</surname><given-names>NM</given-names></name><name><surname>Lehrman</surname><given-names>G</given-names></name><name><surname>Bosch</surname><given-names>RJ</given-names></name><name><surname>Margolis</surname><given-names>DM</given-names></name></person-group><article-title>Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression</article-title><source>Aids</source><year>2004</year><volume>18</volume><issue>8</issue><fpage>1101</fpage><lpage>1108</lpage><pub-id pub-id-type="doi">10.1097/00002030-200405210-00003</pub-id><?supplied-pmid 15166525?><pub-id pub-id-type="pmid">15166525</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Archin</surname><given-names>NM</given-names></name><name><surname>Keedy</surname><given-names>KS</given-names></name><name><surname>Espeseth</surname><given-names>A</given-names></name><name><surname>Dang</surname><given-names>H</given-names></name><name><surname>Hazuda</surname><given-names>DJ</given-names></name><name><surname>Margolis</surname><given-names>DM</given-names></name></person-group><article-title>Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors</article-title><source>Aids</source><year>2009</year><volume>23</volume><issue>14</issue><fpage>1799</fpage><lpage>1806</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32832ec1dc</pub-id><?supplied-pmid 19590405?><pub-id pub-id-type="pmid">19590405</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>HC</given-names></name><name><surname>Xing</surname><given-names>S</given-names></name><name><surname>Shan</surname><given-names>L</given-names></name><name><surname>O'Connell</surname><given-names>K</given-names></name><name><surname>Dinoso</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Shrum</surname><given-names>CK</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>JO</given-names></name><etal/></person-group><article-title>Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation</article-title><source>J Clin Invest</source><year>2009</year><volume>119</volume><issue>11</issue><fpage>3473</fpage><lpage>3486</lpage><?supplied-pmid 19805909?><pub-id pub-id-type="pmid">19805909</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shan</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>K</given-names></name><name><surname>Shroff</surname><given-names>NS</given-names></name><name><surname>Durand</surname><given-names>CM</given-names></name><name><surname>Rabi</surname><given-names>SA</given-names></name><name><surname>Yang</surname><given-names>HC</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Margolick</surname><given-names>JB</given-names></name><name><surname>Blankson</surname><given-names>JN</given-names></name><name><surname>Siliciano</surname><given-names>RF</given-names></name></person-group><article-title>Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation</article-title><source>Immunity</source><year>2012</year><volume>36</volume><issue>3</issue><fpage>491</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.01.014</pub-id><?supplied-pmid 22406268?><pub-id pub-id-type="pmid">22406268</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasmussen</surname><given-names>TA</given-names></name><name><surname>Tolstrup</surname><given-names>M</given-names></name><name><surname>Winckelmann</surname><given-names>A</given-names></name><name><surname>Ostergaard</surname><given-names>L</given-names></name><name><surname>Sogaard</surname><given-names>OS</given-names></name></person-group><article-title>Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials</article-title><source>Hum Vaccin Immunother</source><year>2013</year><volume>9</volume><issue>4</issue><fpage>790</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.4161/hv.23202</pub-id><?supplied-pmid 23563519?><pub-id pub-id-type="pmid">23563519</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirakawa</surname><given-names>K</given-names></name><name><surname>Chavez</surname><given-names>L</given-names></name><name><surname>Hakre</surname><given-names>S</given-names></name><name><surname>Calvanese</surname><given-names>V</given-names></name><name><surname>Verdin</surname><given-names>E</given-names></name></person-group><article-title>Reactivation of latent HIV by histone deacetylase inhibitors</article-title><source>Trends Microbiol</source><year>2013</year><volume>21</volume><issue>6</issue><fpage>277</fpage><lpage>285</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2013.02.005</pub-id><?supplied-pmid 23517573?><pub-id pub-id-type="pmid">23517573</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>J</given-names></name><name><surname>Roe</surname><given-names>K</given-names></name><name><surname>Orillo</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>PY</given-names></name><name><surname>Verma</surname><given-names>S</given-names></name></person-group><article-title>Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection</article-title><source>Antiviral Res</source><year>2015</year><volume>122</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2015.07.008</pub-id><?supplied-pmid 26225754?><pub-id pub-id-type="pmid">26225754</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>AK</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Martineau</surname><given-names>AR</given-names></name></person-group><article-title>Phenylbutyrate Is Bacteriostatic against Mycobacterium tuberculosis and Regulates the Macrophage Response to Infection, Synergistically with 25-Hydroxy-Vitamin D(3)</article-title><source>PLoS Pathog</source><year>2015</year><volume>11</volume><issue>7</issue><fpage>e1005007</fpage><pub-id pub-id-type="doi">10.1371/journal.ppat.1005007</pub-id><?supplied-pmid 26133770?><pub-id pub-id-type="pmid">26133770</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mily</surname><given-names>A</given-names></name><name><surname>Rekha</surname><given-names>RS</given-names></name><name><surname>Kamal</surname><given-names>SM</given-names></name><name><surname>Arifuzzaman</surname><given-names>AS</given-names></name><name><surname>Rahim</surname><given-names>Z</given-names></name><name><surname>Khan</surname><given-names>L</given-names></name><name><surname>Haq</surname><given-names>MA</given-names></name><name><surname>Zaman</surname><given-names>K</given-names></name><name><surname>Bergman</surname><given-names>P</given-names></name><name><surname>Brighenti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>9</issue><fpage>e0138340</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0138340</pub-id><?supplied-pmid 26394045?><pub-id pub-id-type="pmid">26394045</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>RS</given-names></name><name><surname>van Vuuren</surname><given-names>C</given-names></name><name><surname>Potgieter</surname><given-names>S</given-names></name></person-group><article-title>Adalimumab treatment of life-threatening tuberculosis</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><issue>10</issue><fpage>1429</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1086/598504</pub-id><?supplied-pmid 19364287?><pub-id pub-id-type="pmid">19364287</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casarini</surname><given-names>M</given-names></name><name><surname>Ameglio</surname><given-names>F</given-names></name><name><surname>Alemanno</surname><given-names>L</given-names></name><name><surname>Zangrilli</surname><given-names>P</given-names></name><name><surname>Mattia</surname><given-names>P</given-names></name><name><surname>Paone</surname><given-names>G</given-names></name><name><surname>Bisetti</surname><given-names>A</given-names></name><name><surname>Giosue</surname><given-names>S</given-names></name></person-group><article-title>Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>159</volume><issue>1</issue><fpage>143</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.159.1.9803066</pub-id><?supplied-pmid 9872832?><pub-id pub-id-type="pmid">9872832</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>IH</given-names></name><name><surname>Ahmed</surname><given-names>AM</given-names></name><name><surname>Choudhuri</surname><given-names>S</given-names></name><name><surname>Sen</surname><given-names>A</given-names></name><name><surname>Hazra</surname><given-names>A</given-names></name><name><surname>Pal</surname><given-names>NK</given-names></name><name><surname>Bhattacharya</surname><given-names>B</given-names></name><name><surname>Bahar</surname><given-names>B</given-names></name></person-group><article-title>Alteration of serum inflammatory cytokines in active pulmonary tuberculosis following anti-tuberculosis drug therapy</article-title><source>Mol Immunol</source><year>2014</year><volume>62</volume><issue>1</issue><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2014.06.002</pub-id><?supplied-pmid 25019566?><pub-id pub-id-type="pmid">25019566</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>M</given-names></name><name><surname>Kita</surname><given-names>Y</given-names></name><name><surname>Kanamaru</surname><given-names>N</given-names></name><name><surname>Hashimoto</surname><given-names>S</given-names></name><name><surname>Uchiyama</surname><given-names>Y</given-names></name><name><surname>Mihara</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Ohsugi</surname><given-names>Y</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name><name><surname>Sakatani</surname><given-names>M</given-names></name></person-group><article-title>Anti-IL-6 receptor antibody causes less promotion of tuberculosis infection than anti-TNF-alpha antibody in mice</article-title><source>Clin Dev Immunol</source><year>2011</year><volume>2011</volume><fpage>404929</fpage><?supplied-pmid 21603208?><pub-id pub-id-type="pmid">21603208</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimoto</surname><given-names>N</given-names></name><name><surname>Kanakura</surname><given-names>Y</given-names></name><name><surname>Aozasa</surname><given-names>K</given-names></name><name><surname>Johkoh</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name><name><surname>Nakano</surname><given-names>S</given-names></name><name><surname>Nakano</surname><given-names>N</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Nishioka</surname><given-names>K</given-names></name><etal/></person-group><article-title>Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease</article-title><source>Blood</source><year>2005</year><volume>106</volume><issue>8</issue><fpage>2627</fpage><lpage>2632</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-12-4602</pub-id><?supplied-pmid 15998837?><pub-id pub-id-type="pmid">15998837</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Rhee</surname><given-names>F</given-names></name><name><surname>Wong</surname><given-names>RS</given-names></name><name><surname>Munshi</surname><given-names>N</given-names></name><name><surname>Rossi</surname><given-names>JF</given-names></name><name><surname>Ke</surname><given-names>XY</given-names></name><name><surname>Fossa</surname><given-names>A</given-names></name><name><surname>Simpson</surname><given-names>D</given-names></name><name><surname>Capra</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Hsieh</surname><given-names>RK</given-names></name><etal/></person-group><article-title>Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Oncol</source><year>2014</year><volume>15</volume><issue>9</issue><fpage>966</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(14)70319-5</pub-id><?supplied-pmid 25042199?><pub-id pub-id-type="pmid">25042199</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Duan</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>Interleukin-6 signaling pathway in targeted therapy for cancer</article-title><source>Cancer Treat Rev</source><year>2012</year><volume>38</volume><issue>7</issue><fpage>904</fpage><lpage>910</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2012.04.007</pub-id><?supplied-pmid 22651903?><pub-id pub-id-type="pmid">22651903</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Datta</surname><given-names>M</given-names></name><name><surname>Via</surname><given-names>LE</given-names></name><name><surname>Kamoun</surname><given-names>WS</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Seano</surname><given-names>G</given-names></name><name><surname>Weiner</surname><given-names>DM</given-names></name><name><surname>Schimel</surname><given-names>D</given-names></name><name><surname>England</surname><given-names>K</given-names></name><name><surname>Martin</surname><given-names>JD</given-names></name><etal/></person-group><article-title>Anti-vascular endothelial growth factor treatment normalizes tuberculosis granuloma vasculature and improves small molecule delivery</article-title><source>Proc Natl Acad Sci U S A</source><year>2015</year><volume>112</volume><issue>6</issue><fpage>1827</fpage><lpage>1832</lpage><pub-id pub-id-type="doi">10.1073/pnas.1424563112</pub-id><?supplied-pmid 25624495?><pub-id pub-id-type="pmid">25624495</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oehlers</surname><given-names>SH</given-names></name><name><surname>Cronan</surname><given-names>MR</given-names></name><name><surname>Scott</surname><given-names>NR</given-names></name><name><surname>Thomas</surname><given-names>MI</given-names></name><name><surname>Okuda</surname><given-names>KS</given-names></name><name><surname>Walton</surname><given-names>EM</given-names></name><name><surname>Beerman</surname><given-names>RW</given-names></name><name><surname>Crosier</surname><given-names>PS</given-names></name><name><surname>Tobin</surname><given-names>DM</given-names></name></person-group><article-title>Interception of host angiogenic signalling limits mycobacterial growth</article-title><source>Nature</source><year>2015</year><volume>517</volume><issue>7536</issue><fpage>612</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1038/nature13967</pub-id><?supplied-pmid 25470057?><pub-id pub-id-type="pmid">25470057</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veenstra</surname><given-names>H</given-names></name><name><surname>Baumann</surname><given-names>R</given-names></name><name><surname>Lukey</surname><given-names>PT</given-names></name><name><surname>Beyers</surname><given-names>N</given-names></name><name><surname>van Helden</surname><given-names>PD</given-names></name><name><surname>Walzl</surname><given-names>G</given-names></name></person-group><article-title>High levels of intracellular IL-4 are expressed in circulating apoptotic T cells in patients with tuberculosis and in community controls</article-title><source>Tuberculosis</source><year>2008</year><volume>88</volume><issue>1</issue><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2007.09.001</pub-id><?supplied-pmid 17977794?><pub-id pub-id-type="pmid">17977794</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>T</given-names></name><name><surname>Beyers</surname><given-names>N</given-names></name><name><surname>Aguirre</surname><given-names>A</given-names></name><name><surname>Walzl</surname><given-names>G</given-names></name></person-group><article-title>Immunosuppression during active tuberculosis is characterized by decreased interferon- gamma production and CD25 expression with elevated forkhead box P3, transforming growth factor- beta, and interleukin-4 mRNA levels</article-title><source>J Infect Dis</source><year>2007</year><volume>195</volume><issue>6</issue><fpage>870</fpage><lpage>878</lpage><pub-id pub-id-type="doi">10.1086/511277</pub-id><?supplied-pmid 17299718?><pub-id pub-id-type="pmid">17299718</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heitmann</surname><given-names>L</given-names></name><name><surname>Abad Dar</surname><given-names>M</given-names></name><name><surname>Schreiber</surname><given-names>T</given-names></name><name><surname>Erdmann</surname><given-names>H</given-names></name><name><surname>Behrends</surname><given-names>J</given-names></name><name><surname>McKenzie</surname><given-names>AN</given-names></name><name><surname>Brombacher</surname><given-names>F</given-names></name><name><surname>Ehlers</surname><given-names>S</given-names></name><name><surname>Holscher</surname><given-names>C</given-names></name></person-group><article-title>The IL-13/IL-4Ralpha axis is involved in tuberculosis-associated pathology</article-title><source>J Pathol</source><year>2014</year><volume>234</volume><issue>3</issue><fpage>338</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1002/path.4399</pub-id><?supplied-pmid 24979482?><pub-id pub-id-type="pmid">24979482</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name></person-group><article-title>Expression of TNF-alpha, IFN-gamma, TGF-beta, and IL-4 in the spinal tuberculous focus and its impact on the disease</article-title><source>Cell Biochem Biophys</source><year>2014</year><volume>70</volume><issue>3</issue><fpage>1759</fpage><lpage>1764</lpage><pub-id pub-id-type="doi">10.1007/s12013-014-0125-z</pub-id><?supplied-pmid 25326857?><pub-id pub-id-type="pmid">25326857</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>S</given-names></name><name><surname>Rehn</surname><given-names>A</given-names></name><name><surname>Rahman</surname><given-names>J</given-names></name><name><surname>Andersson</surname><given-names>J</given-names></name><name><surname>Svensson</surname><given-names>M</given-names></name><name><surname>Brighenti</surname><given-names>S</given-names></name></person-group><article-title>Pulmonary tuberculosis patients with a vitamin D deficiency demonstrate low local expression of the antimicrobial peptide LL-37 but enhanced FoxP3 regulatory T cells and IgG-secreting cells</article-title><source>Clin Immunol</source><year>2014</year><volume>156</volume><issue>2</issue><fpage>85</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.clim.2014.12.003</pub-id><?supplied-pmid 25510482?><pub-id pub-id-type="pmid">25510482</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montoya</surname><given-names>D</given-names></name><name><surname>Inkeles</surname><given-names>MS</given-names></name><name><surname>Liu</surname><given-names>PT</given-names></name><name><surname>Realegeno</surname><given-names>S</given-names></name><name><surname>Teles</surname><given-names>RM</given-names></name><name><surname>Vaidya</surname><given-names>P</given-names></name><name><surname>Munoz</surname><given-names>MA</given-names></name><name><surname>Schenk</surname><given-names>M</given-names></name><name><surname>Swindell</surname><given-names>WR</given-names></name><name><surname>Chun</surname><given-names>R</given-names></name><etal/></person-group><article-title>IL-32 is a molecular marker of a host defense network in human tuberculosis</article-title><source>Sci Transl Med</source><year>2014</year><volume>6</volume><issue>250</issue><fpage>250ra114</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3009546</pub-id><?supplied-pmid 25143364?><pub-id pub-id-type="pmid">25143364</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klug-Micu</surname><given-names>GM</given-names></name><name><surname>Stenger</surname><given-names>S</given-names></name><name><surname>Sommer</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>PT</given-names></name><name><surname>Krutzik</surname><given-names>SR</given-names></name><name><surname>Modlin</surname><given-names>RL</given-names></name><name><surname>Fabri</surname><given-names>M</given-names></name></person-group><article-title>CD40 ligand and interferon-gamma induce an antimicrobial response against Mycobacterium tuberculosis in human monocytes</article-title><source>Immunology</source><year>2013</year><volume>139</volume><issue>1</issue><fpage>121</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1111/imm.12062</pub-id><?supplied-pmid 23289765?><pub-id pub-id-type="pmid">23289765</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daley</surname><given-names>P</given-names></name><name><surname>Jagannathan</surname><given-names>V</given-names></name><name><surname>John</surname><given-names>KR</given-names></name><name><surname>Sarojini</surname><given-names>J</given-names></name><name><surname>Latha</surname><given-names>A</given-names></name><name><surname>Vieth</surname><given-names>R</given-names></name><name><surname>Suzana</surname><given-names>S</given-names></name><name><surname>Jeyaseelan</surname><given-names>L</given-names></name><name><surname>Christopher</surname><given-names>DJ</given-names></name><name><surname>Smieja</surname><given-names>M</given-names></name><etal/></person-group><article-title>Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Infect Dis</source><year>2015</year><volume>15</volume><issue>5</issue><fpage>528</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)70053-8</pub-id><?supplied-pmid 25863562?><pub-id pub-id-type="pmid">25863562</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tukvadze</surname><given-names>N</given-names></name><name><surname>Sanikidze</surname><given-names>E</given-names></name><name><surname>Kipiani</surname><given-names>M</given-names></name><name><surname>Hebbar</surname><given-names>G</given-names></name><name><surname>Easley</surname><given-names>KA</given-names></name><name><surname>Shenvi</surname><given-names>N</given-names></name><name><surname>Kempker</surname><given-names>RR</given-names></name><name><surname>Frediani</surname><given-names>JK</given-names></name><name><surname>Mirtskhulava</surname><given-names>V</given-names></name><name><surname>Alvarez</surname><given-names>JA</given-names></name><etal/></person-group><article-title>High-dose vitamin D3 in adults with pulmonary tuberculosis: a double-blind randomized controlled trial</article-title><source>Am J Clin Nutr</source><year>2015</year><volume>102</volume><issue>5</issue><fpage>1059</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.3945/ajcn.115.113886</pub-id><?supplied-pmid 26399865?><pub-id pub-id-type="pmid">26399865</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azoury</surname><given-names>SC</given-names></name><name><surname>Straughan</surname><given-names>DM</given-names></name><name><surname>Shukla</surname><given-names>V</given-names></name></person-group><article-title>Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety</article-title><source>Curr Cancer Drug Targets</source><year>2015</year><volume>15</volume><issue>6</issue><fpage>452</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.2174/156800961506150805145120</pub-id><?supplied-pmid 26282545?><pub-id pub-id-type="pmid">26282545</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardoll</surname><given-names>DM</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source>Nat Rev Cancer</source><year>2012</year><volume>12</volume><issue>4</issue><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrc3239</pub-id><?supplied-pmid 22437870?><pub-id pub-id-type="pmid">22437870</pub-id></element-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>J</given-names></name><name><surname>Suh</surname><given-names>WK</given-names></name></person-group><article-title>The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy</article-title><source>Immune Netw</source><year>2014</year><volume>14</volume><issue>6</issue><fpage>265</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.4110/in.2014.14.6.265</pub-id><?supplied-pmid 25550693?><pub-id pub-id-type="pmid">25550693</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francisco</surname><given-names>LM</given-names></name><name><surname>Sage</surname><given-names>PT</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name></person-group><article-title>The PD-1 pathway in tolerance and autoimmunity</article-title><source>Immunol Rev</source><year>2010</year><volume>236</volume><fpage>219</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2010.00923.x</pub-id><?supplied-pmid 20636820?><pub-id pub-id-type="pmid">20636820</pub-id></element-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srahna</surname><given-names>M</given-names></name><name><surname>Van Grunsven</surname><given-names>LA</given-names></name><name><surname>Remacle</surname><given-names>JE</given-names></name><name><surname>Vandenberghe</surname><given-names>P</given-names></name></person-group><article-title>CTLA-4 interacts with STAT5 and inhibits STAT5-mediated transcription</article-title><source>Immunology</source><year>2006</year><volume>117</volume><issue>3</issue><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2005.02313.x</pub-id><?supplied-pmid 16476059?><pub-id pub-id-type="pmid">16476059</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>LT</given-names></name><name><surname>Ohashi</surname><given-names>PS</given-names></name></person-group><article-title>Clinical blockade of PD1 and LAG3 - potential mechanisms of action</article-title><source>Nat Rev Immunol</source><year>2014</year><volume>15</volume><issue>1</issue><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1038/nri3790</pub-id><pub-id pub-id-type="pmid">25534622</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Allison</surname><given-names>JP</given-names></name></person-group><article-title>The future of immune checkpoint therapy</article-title><source>Science</source><year>2015</year><volume>348</volume><issue>6230</issue><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1126/science.aaa8172</pub-id><?supplied-pmid 25838373?><pub-id pub-id-type="pmid">25838373</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardiner</surname><given-names>D</given-names></name><name><surname>Lalezari</surname><given-names>J</given-names></name><name><surname>Lawitz</surname><given-names>E</given-names></name><name><surname>DiMicco</surname><given-names>M</given-names></name><name><surname>Ghalib</surname><given-names>R</given-names></name><name><surname>Reddy</surname><given-names>KR</given-names></name><name><surname>Chang</surname><given-names>KM</given-names></name><name><surname>Sulkowski</surname><given-names>M</given-names></name><name><surname>Marro</surname><given-names>SO</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><etal/></person-group><article-title>A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>5</issue><fpage>e63818</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0063818</pub-id><?supplied-pmid 23717490?><pub-id pub-id-type="pmid">23717490</pub-id></element-citation></ref><ref id="CR98"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurado</surname><given-names>JO</given-names></name><name><surname>Alvarez</surname><given-names>IB</given-names></name><name><surname>Pasquinelli</surname><given-names>V</given-names></name><name><surname>Martinez</surname><given-names>GJ</given-names></name><name><surname>Quiroga</surname><given-names>MF</given-names></name><name><surname>Abbate</surname><given-names>E</given-names></name><name><surname>Musella</surname><given-names>RM</given-names></name><name><surname>Chuluyan</surname><given-names>HE</given-names></name><name><surname>Garcia</surname><given-names>VE</given-names></name></person-group><article-title>Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis</article-title><source>J Immunol</source><year>2008</year><volume>181</volume><issue>1</issue><fpage>116</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.181.1.116</pub-id><?supplied-pmid 18566376?><pub-id pub-id-type="pmid">18566376</pub-id></element-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Mohan</surname><given-names>A</given-names></name><name><surname>Dey</surname><given-names>AB</given-names></name><name><surname>Mitra</surname><given-names>DK</given-names></name></person-group><article-title>Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis</article-title><source>J Infect Dis</source><year>2013</year><volume>208</volume><issue>4</issue><fpage>603</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1093/infdis/jit206</pub-id><?supplied-pmid 23661793?><pub-id pub-id-type="pmid">23661793</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hassan</surname><given-names>SS</given-names></name><name><surname>Akram</surname><given-names>M</given-names></name><name><surname>King</surname><given-names>EC</given-names></name><name><surname>Dockrell</surname><given-names>HM</given-names></name><name><surname>Cliff</surname><given-names>JM</given-names></name></person-group><article-title>PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Protein during the Intensive Phase of Tuberculosis Treatment</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><issue>9</issue><fpage>e0137646</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0137646</pub-id><?supplied-pmid 26359860?><pub-id pub-id-type="pmid">26359860</pub-id></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNab</surname><given-names>FW</given-names></name><name><surname>Berry</surname><given-names>MP</given-names></name><name><surname>Graham</surname><given-names>CM</given-names></name><name><surname>Bloch</surname><given-names>SA</given-names></name><name><surname>Oni</surname><given-names>T</given-names></name><name><surname>Wilkinson</surname><given-names>KA</given-names></name><name><surname>Wilkinson</surname><given-names>RJ</given-names></name><name><surname>Kon</surname><given-names>OM</given-names></name><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Chaussabel</surname><given-names>D</given-names></name><etal/></person-group><article-title>Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis</article-title><source>Eur J Immunol</source><year>2011</year><volume>41</volume><issue>7</issue><fpage>1941</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1002/eji.201141421</pub-id><?supplied-pmid 21509782?><pub-id pub-id-type="pmid">21509782</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Dey</surname><given-names>AB</given-names></name><name><surname>Mohan</surname><given-names>A</given-names></name><name><surname>Mitra</surname><given-names>DK</given-names></name></person-group><article-title>Programmed death-1 receptor suppresses gamma-IFN producing NKT cells in human tuberculosis</article-title><source>Tuberculosis</source><year>2014</year><volume>94</volume><issue>3</issue><fpage>197</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2014.01.005</pub-id><?supplied-pmid 24629634?><pub-id pub-id-type="pmid">24629634</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia Jacobo</surname><given-names>RE</given-names></name><name><surname>Serrano</surname><given-names>CJ</given-names></name><name><surname>Enciso Moreno</surname><given-names>JA</given-names></name><name><surname>Gaspar Ramirez</surname><given-names>O</given-names></name><name><surname>Trujillo Ochoa</surname><given-names>JL</given-names></name><name><surname>Uresti Rivera</surname><given-names>EE</given-names></name><name><surname>Portales Perez</surname><given-names>DP</given-names></name><name><surname>Gonzalez-Amaro</surname><given-names>R</given-names></name><name><surname>Garcia Hernandez</surname><given-names>MH</given-names></name></person-group><article-title>Analysis of Th1, Th17 and regulatory T cells in tuberculosis case contacts</article-title><source>Cell Immunol</source><year>2014</year><volume>289</volume><issue>1-2</issue><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2014.03.010</pub-id><?supplied-pmid 24841855?><pub-id pub-id-type="pmid">24841855</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlo</surname><given-names>A</given-names></name><name><surname>Saverino</surname><given-names>D</given-names></name><name><surname>Tenca</surname><given-names>C</given-names></name><name><surname>Grossi</surname><given-names>CE</given-names></name><name><surname>Bruno</surname><given-names>S</given-names></name><name><surname>Ciccone</surname><given-names>E</given-names></name></person-group><article-title>CD85/LIR-1/ILT2 and CD152 (cytotoxic T lymphocyte antigen 4) inhibitory molecules down-regulate the cytolytic activity of human CD4+ T-cell clones specific for Mycobacterium tuberculosis</article-title><source>Infect Immun</source><year>2001</year><volume>69</volume><issue>10</issue><fpage>6022</fpage><lpage>6029</lpage><pub-id pub-id-type="doi">10.1128/IAI.69.10.6022-6029.2001</pub-id><?supplied-pmid 11553539?><pub-id pub-id-type="pmid">11553539</pub-id></element-citation></ref><ref id="CR105"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sierro</surname><given-names>S</given-names></name><name><surname>Romero</surname><given-names>P</given-names></name><name><surname>Speiser</surname><given-names>DE</given-names></name></person-group><article-title>The CD4-like molecule LAG-3, biology and therapeutic applications</article-title><source>Expert Opin Ther Targets</source><year>2011</year><volume>15</volume><issue>1</issue><fpage>91</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1517/14712598.2011.540563</pub-id><?supplied-pmid 21142803?><pub-id pub-id-type="pmid">21142803</pub-id></element-citation></ref><ref id="CR106"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phillips</surname><given-names>BL</given-names></name><name><surname>Mehra</surname><given-names>S</given-names></name><name><surname>Ahsan</surname><given-names>MH</given-names></name><name><surname>Selman</surname><given-names>M</given-names></name><name><surname>Khader</surname><given-names>SA</given-names></name><name><surname>Kaushal</surname><given-names>D</given-names></name></person-group><article-title>LAG3 Expression in Active Mycobacterium tuberculosis Infections</article-title><source>Am J Pathol</source><year>2014</year></element-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Butler</surname><given-names>NS</given-names></name><name><surname>Moebius</surname><given-names>J</given-names></name><name><surname>Pewe</surname><given-names>LL</given-names></name><name><surname>Traore</surname><given-names>B</given-names></name><name><surname>Doumbo</surname><given-names>OK</given-names></name><name><surname>Tygrett</surname><given-names>LT</given-names></name><name><surname>Waldschmidt</surname><given-names>TJ</given-names></name><name><surname>Crompton</surname><given-names>PD</given-names></name><name><surname>Harty</surname><given-names>JT</given-names></name></person-group><article-title>Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection</article-title><source>Nat Immunol</source><year>2012</year><volume>13</volume><issue>2</issue><fpage>188</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1038/ni.2180</pub-id><pub-id pub-id-type="pmid">22157630</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngiow</surname><given-names>SF</given-names></name><name><surname>Teng</surname><given-names>MW</given-names></name><name><surname>Smyth</surname><given-names>MJ</given-names></name></person-group><article-title>Prospects for TIM3-Targeted Antitumor Immunotherapy</article-title><source>Cancer Res</source><year>2011</year><volume>71</volume><issue>21</issue><fpage>6567</fpage><lpage>6571</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1487</pub-id><?supplied-pmid 22009533?><pub-id pub-id-type="pmid">22009533</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sada-Ovalle</surname><given-names>I</given-names></name><name><surname>Chavez-Galan</surname><given-names>L</given-names></name><name><surname>Torre-Bouscoulet</surname><given-names>L</given-names></name><name><surname>Nava-Gamino</surname><given-names>L</given-names></name><name><surname>Barrera</surname><given-names>L</given-names></name><name><surname>Jayaraman</surname><given-names>P</given-names></name><name><surname>Torres-Rojas</surname><given-names>M</given-names></name><name><surname>Salazar-Lezama</surname><given-names>MA</given-names></name><name><surname>Behar</surname><given-names>SM</given-names></name></person-group><article-title>The Tim3-galectin 9 pathway induces antibacterial activity in human macrophages infected with Mycobacterium tuberculosis</article-title><source>J Immunol</source><year>2012</year><volume>189</volume><issue>12</issue><fpage>5896</fpage><lpage>5902</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200990</pub-id><?supplied-pmid 23180819?><pub-id pub-id-type="pmid">23180819</pub-id></element-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sada-Ovalle</surname><given-names>I</given-names></name><name><surname>Ocana-Guzman</surname><given-names>R</given-names></name><name><surname>Perez-Patrigeon</surname><given-names>S</given-names></name><name><surname>Chavez-Galan</surname><given-names>L</given-names></name><name><surname>Sierra-Madero</surname><given-names>J</given-names></name><name><surname>Torre-Bouscoulet</surname><given-names>L</given-names></name><name><surname>Addo</surname><given-names>MM</given-names></name></person-group><article-title>Tim-3 blocking rescue macrophage and T cell function against Mycobacterium tuberculosis infection in HIV+ patients</article-title><source>J Int AIDS Soc</source><year>2015</year><volume>18</volume><issue>1</issue><fpage>20078</fpage><pub-id pub-id-type="doi">10.7448/IAS.18.1.20078</pub-id><?supplied-pmid 26486200?><pub-id pub-id-type="pmid">26486200</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parida</surname><given-names>SK</given-names></name><name><surname>Poiret</surname><given-names>T</given-names></name><name><surname>Zhenjiang</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Heyckendorf</surname><given-names>J</given-names></name><name><surname>Lange</surname><given-names>C</given-names></name><name><surname>Ambati</surname><given-names>AS</given-names></name><name><surname>Rao</surname><given-names>MV</given-names></name><name><surname>Valentini</surname><given-names>D</given-names></name><name><surname>Ferrara</surname><given-names>G</given-names></name><etal/></person-group><article-title>T-Cell Therapy: Options for Infectious Diseases</article-title><source>Clin Infect Dis</source><year>2015</year><volume>61</volume><issue>suppl 3</issue><fpage>S217</fpage><lpage>S224</lpage><pub-id pub-id-type="doi">10.1093/cid/civ615</pub-id><?supplied-pmid 26409284?><pub-id pub-id-type="pmid">26409284</pub-id></element-citation></ref><ref id="CR112"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parida</surname><given-names>SK</given-names></name><name><surname>Madansein</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Padayatchi</surname><given-names>N</given-names></name><name><surname>Master</surname><given-names>I</given-names></name><name><surname>Naidu</surname><given-names>K</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name></person-group><article-title>Cellular therapy in tuberculosis</article-title><source>Int J Infect Dis</source><year>2015</year><volume>32</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2015.01.016</pub-id><?supplied-pmid 25809753?><pub-id pub-id-type="pmid">25809753</pub-id></element-citation></ref><ref id="CR113"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Restifo</surname><given-names>NP</given-names></name></person-group><article-title>Adoptive cell transfer as personalized immunotherapy for human cancer</article-title><source>Science</source><year>2015</year><volume>348</volume><issue>6230</issue><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4967</pub-id><?supplied-pmid 25838374?><pub-id pub-id-type="pmid">25838374</pub-id></element-citation></ref><ref id="CR114"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skrahin</surname><given-names>A</given-names></name><name><surname>Ahmed</surname><given-names>RK</given-names></name><name><surname>Ferrara</surname><given-names>G</given-names></name><name><surname>Rane</surname><given-names>L</given-names></name><name><surname>Poiret</surname><given-names>T</given-names></name><name><surname>Isaikina</surname><given-names>Y</given-names></name><name><surname>Skrahina</surname><given-names>A</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Maeurer</surname><given-names>MJ</given-names></name></person-group><article-title>Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial</article-title><source>Lancet Respir Med</source><year>2014</year><volume>2</volume><issue>2</issue><fpage>108</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(13)70234-0</pub-id><?supplied-pmid 24503266?><pub-id pub-id-type="pmid">24503266</pub-id></element-citation></ref><ref id="CR115"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>S</given-names></name><name><surname>Mehra</surname><given-names>V</given-names></name><name><surname>Thoma-Uszynski</surname><given-names>S</given-names></name><name><surname>Stenger</surname><given-names>S</given-names></name><name><surname>Serbina</surname><given-names>N</given-names></name><name><surname>Mazzaccaro</surname><given-names>RJ</given-names></name><name><surname>Flynn</surname><given-names>JL</given-names></name><name><surname>Barnes</surname><given-names>PF</given-names></name><name><surname>Southwood</surname><given-names>S</given-names></name><name><surname>Celis</surname><given-names>E</given-names></name><etal/></person-group><article-title>Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis</article-title><source>Proc Natl Acad Sci U S A</source><year>2000</year><volume>97</volume><issue>22</issue><fpage>12210</fpage><lpage>12215</lpage><pub-id pub-id-type="doi">10.1073/pnas.210391497</pub-id><?supplied-pmid 11035787?><pub-id pub-id-type="pmid">11035787</pub-id></element-citation></ref><ref id="CR116"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mustafa</surname><given-names>AS</given-names></name><name><surname>Oftung</surname><given-names>F</given-names></name><name><surname>Amoudy</surname><given-names>HA</given-names></name><name><surname>Madi</surname><given-names>NM</given-names></name><name><surname>Abal</surname><given-names>AT</given-names></name><name><surname>Shaban</surname><given-names>F</given-names></name><name><surname>Rosen Krands</surname><given-names>I</given-names></name><name><surname>Andersen</surname><given-names>P</given-names></name></person-group><article-title>Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines</article-title><source>Clin Infect Dis</source><year>2000</year><volume>30</volume><issue>Suppl 3</issue><fpage>S201</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1086/313862</pub-id><?supplied-pmid 10875783?><pub-id pub-id-type="pmid">10875783</pub-id></element-citation></ref><ref id="CR117"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasmar</surname><given-names>AG</given-names></name><name><surname>Van Rhijn</surname><given-names>I</given-names></name><name><surname>Magalhaes</surname><given-names>KG</given-names></name><name><surname>Young</surname><given-names>DC</given-names></name><name><surname>Cheng</surname><given-names>TY</given-names></name><name><surname>Turner</surname><given-names>MT</given-names></name><name><surname>Schiefner</surname><given-names>A</given-names></name><name><surname>Kalathur</surname><given-names>RC</given-names></name><name><surname>Wilson</surname><given-names>IA</given-names></name><name><surname>Bhati</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cutting Edge: CD1a tetramers and dextramers identify human lipopeptide-specific T cells ex vivo</article-title><source>J Immunol</source><year>2013</year><volume>191</volume><issue>9</issue><fpage>4499</fpage><lpage>4503</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1301660</pub-id><?supplied-pmid 24089190?><pub-id pub-id-type="pmid">24089190</pub-id></element-citation></ref><ref id="CR118"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Axelsson-Robertson</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><name><surname>Loxton</surname><given-names>AG</given-names></name><name><surname>Walzl</surname><given-names>G</given-names></name><name><surname>Bates</surname><given-names>M</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name></person-group><article-title>Frequency of Mycobacterium tuberculosis-specific CD8+ T-cells in the course of anti-tuberculosis treatment</article-title><source>Int J Infect Dis</source><year>2015</year><volume>32</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2015.01.017</pub-id><?supplied-pmid 25809751?><pub-id pub-id-type="pmid">25809751</pub-id></element-citation></ref><ref id="CR119"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Daker</surname><given-names>S</given-names></name><name><surname>Sacchi</surname><given-names>A</given-names></name><name><surname>Montesano</surname><given-names>C</given-names></name><name><surname>Altieri</surname><given-names>AM</given-names></name><name><surname>Galluccio</surname><given-names>G</given-names></name><name><surname>Colizzi</surname><given-names>V</given-names></name><name><surname>Martini</surname><given-names>F</given-names></name><name><surname>Martino</surname><given-names>A</given-names></name></person-group><article-title>An abnormal phenotype of lung Vgamma9Vdelta2 T cells impairs their responsiveness in tuberculosis patients</article-title><source>Cell Immunol</source><year>2013</year><volume>282</volume><issue>2</issue><fpage>106</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2013.05.001</pub-id><?supplied-pmid 23770719?><pub-id pub-id-type="pmid">23770719</pub-id></element-citation></ref><ref id="CR120"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beeson</surname><given-names>CC</given-names></name><name><surname>Beeson</surname><given-names>GC</given-names></name><name><surname>Schnellmann</surname><given-names>RG</given-names></name></person-group><article-title>A high-throughput respirometric assay for mitochondrial biogenesis and toxicity</article-title><source>Anal Biochem</source><year>2010</year><volume>404</volume><issue>1</issue><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2010.04.040</pub-id><?supplied-pmid 20465991?><pub-id pub-id-type="pmid">20465991</pub-id></element-citation></ref><ref id="CR121"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roca</surname><given-names>FJ</given-names></name><name><surname>Ramakrishnan</surname><given-names>L</given-names></name></person-group><article-title>TNF dually mediates resistance and susceptibility to mycobacteria via mitochondrial reactive oxygen species</article-title><source>Cell</source><year>2013</year><volume>153</volume><issue>3</issue><fpage>521</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.022</pub-id><?supplied-pmid 23582643?><pub-id pub-id-type="pmid">23582643</pub-id></element-citation></ref><ref id="CR122"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehrman</surname><given-names>G</given-names></name><name><surname>Hogue</surname><given-names>IB</given-names></name><name><surname>Palmer</surname><given-names>S</given-names></name><name><surname>Jennings</surname><given-names>C</given-names></name><name><surname>Spina</surname><given-names>CA</given-names></name><name><surname>Wiegand</surname><given-names>A</given-names></name><name><surname>Landay</surname><given-names>AL</given-names></name><name><surname>Coombs</surname><given-names>RW</given-names></name><name><surname>Richman</surname><given-names>DD</given-names></name><name><surname>Mellors</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Depletion of latent HIV-1 infection in vivo: a proof-of-concept study</article-title><source>Lancet</source><year>2005</year><volume>366</volume><issue>9485</issue><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(05)67098-5</pub-id><?supplied-pmid 16099290?><pub-id pub-id-type="pmid">16099290</pub-id></element-citation></ref><ref id="CR123"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tung</surname><given-names>EW</given-names></name><name><surname>Winn</surname><given-names>LM</given-names></name></person-group><article-title>Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects</article-title><source>Mol Pharmacol</source><year>2011</year><volume>80</volume><issue>6</issue><fpage>979</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1124/mol.111.072314</pub-id><?supplied-pmid 21868484?><pub-id pub-id-type="pmid">21868484</pub-id></element-citation></ref><ref id="CR124"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiebler</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>K</given-names></name><name><surname>Hegyi</surname><given-names>K</given-names></name><name><surname>Newton</surname><given-names>SM</given-names></name><name><surname>Renna</surname><given-names>M</given-names></name><name><surname>Hepburn</surname><given-names>L</given-names></name><name><surname>Klapholz</surname><given-names>C</given-names></name><name><surname>Coulter</surname><given-names>S</given-names></name><name><surname>Obregon-Henao</surname><given-names>A</given-names></name><name><surname>Henao Tamayo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion</article-title><source>EMBO Mol Med</source><year>2015</year><volume>7</volume><issue>2</issue><fpage>127</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.15252/emmm.201404137</pub-id><pub-id pub-id-type="pmid">25535254</pub-id></element-citation></ref><ref id="CR125"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>JA</given-names></name><name><surname>Lam</surname><given-names>S</given-names></name><name><surname>Garrido</surname><given-names>C</given-names></name><name><surname>Archin</surname><given-names>N</given-names></name><name><surname>Rooney</surname><given-names>CM</given-names></name><name><surname>Bollard</surname><given-names>CM</given-names></name><name><surname>Margolis</surname><given-names>DM</given-names></name></person-group><article-title>Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir</article-title><source>J Infect Dis</source><year>2015</year><?supplied-pmid 25589335?><pub-id pub-id-type="pmid">25589335</pub-id></element-citation></ref><ref id="CR126"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petruccelli</surname><given-names>LA</given-names></name><name><surname>Dupere-Richer</surname><given-names>D</given-names></name><name><surname>Pettersson</surname><given-names>F</given-names></name><name><surname>Retrouvey</surname><given-names>H</given-names></name><name><surname>Skoulikas</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>WH</given-names><suffix>Jr</suffix></name></person-group><article-title>Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><issue>6</issue><fpage>e20987</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0020987</pub-id><?supplied-pmid 21695163?><pub-id pub-id-type="pmid">21695163</pub-id></element-citation></ref><ref id="CR127"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>PA</given-names></name><name><surname>Richon</surname><given-names>VM</given-names></name><name><surname>Kelly</surname><given-names>WK</given-names></name><name><surname>Chiao</surname><given-names>JH</given-names></name><name><surname>Miller</surname><given-names>T</given-names></name></person-group><article-title>Histone deacetylase inhibitors: development as cancer therapy</article-title><source>Novartis Found Symp</source><year>2004</year><volume>259</volume><fpage>269</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1002/0470862637.ch20</pub-id><?supplied-pmid 15171260?><pub-id pub-id-type="pmid">15171260</pub-id></element-citation></ref><ref id="CR128"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>NN</given-names></name><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Huehnken</surname><given-names>C</given-names></name><name><surname>Agerberth</surname><given-names>B</given-names></name><name><surname>Gudmundsson</surname><given-names>GH</given-names></name></person-group><article-title>Phenylbutyrate induces cathelicidin expression via the vitamin D receptor: Linkage to inflammatory and growth factor cytokines pathways</article-title><source>Mol Immunol</source><year>2015</year><volume>63</volume><issue>2</issue><fpage>530</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2014.10.007</pub-id><?supplied-pmid 25458314?><pub-id pub-id-type="pmid">25458314</pub-id></element-citation></ref><ref id="CR129"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name></person-group><article-title>Selective depletion of CD4&#x02009;+&#x02009;CD25&#x02009;+&#x02009;Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels</article-title><source>Cancer Res</source><year>2010</year><volume>70</volume><issue>12</issue><fpage>4850</fpage><lpage>4858</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0283</pub-id><?supplied-pmid 20501849?><pub-id pub-id-type="pmid">20501849</pub-id></element-citation></ref><ref id="CR130"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henter</surname><given-names>JI</given-names></name><name><surname>Palmkvist-Kaijser</surname><given-names>K</given-names></name><name><surname>Holzgraefe</surname><given-names>B</given-names></name><name><surname>Bryceson</surname><given-names>YT</given-names></name><name><surname>Palmer</surname><given-names>K</given-names></name></person-group><article-title>Cytotoxic therapy for severe swine flu A/H1N1</article-title><source>Lancet</source><year>2010</year><volume>376</volume><issue>9758</issue><fpage>2116</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(10)61345-1</pub-id><?supplied-pmid 21168053?><pub-id pub-id-type="pmid">21168053</pub-id></element-citation></ref><ref id="CR131"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pirinen</surname><given-names>E</given-names></name><name><surname>Canto</surname><given-names>C</given-names></name><name><surname>Jo</surname><given-names>YS</given-names></name><name><surname>Morato</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Menzies</surname><given-names>KJ</given-names></name><name><surname>Williams</surname><given-names>EG</given-names></name><name><surname>Mouchiroud</surname><given-names>L</given-names></name><name><surname>Moullan</surname><given-names>N</given-names></name><name><surname>Hagberg</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle</article-title><source>Cell Metab</source><year>2014</year><volume>19</volume><issue>6</issue><fpage>1034</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.04.002</pub-id><?supplied-pmid 24814482?><pub-id pub-id-type="pmid">24814482</pub-id></element-citation></ref><ref id="CR132"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Bates</surname><given-names>M</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name></person-group><article-title>Corticosteroid therapy for pneumonia</article-title><source>Lancet</source><year>2015</year><volume>386</volume><issue>9997</issue><fpage>955</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(15)00065-3</pub-id><?supplied-pmid 26369471?><pub-id pub-id-type="pmid">26369471</pub-id></element-citation></ref><ref id="CR133"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>NP</given-names></name><name><surname>Hegde</surname><given-names>VL</given-names></name><name><surname>Hofseth</surname><given-names>LJ</given-names></name><name><surname>Nagarkatti</surname><given-names>M</given-names></name><name><surname>Nagarkatti</surname><given-names>P</given-names></name></person-group><article-title>Resveratrol (trans-3,5,4&#x02032;-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor</article-title><source>Mol Pharmacol</source><year>2007</year><volume>72</volume><issue>6</issue><fpage>1508</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1124/mol.107.038984</pub-id><?supplied-pmid 17872969?><pub-id pub-id-type="pmid">17872969</pub-id></element-citation></ref><ref id="CR134"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estrella</surname><given-names>JL</given-names></name><name><surname>Kan-Sutton</surname><given-names>C</given-names></name><name><surname>Gong</surname><given-names>X</given-names></name><name><surname>Rajagopalan</surname><given-names>M</given-names></name><name><surname>Lewis</surname><given-names>DE</given-names></name><name><surname>Hunter</surname><given-names>RL</given-names></name><name><surname>Eissa</surname><given-names>NT</given-names></name><name><surname>Jagannath</surname><given-names>C</given-names></name></person-group><article-title>A Novel in vitro Human Macrophage Model to Study the Persistence of Mycobacterium tuberculosis Using Vitamin D(3) and Retinoic Acid Activated THP-1 Macrophages</article-title><source>Front Microbiol</source><year>2011</year><volume>2</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.3389/fmicb.2011.00067</pub-id><?supplied-pmid 21747789?><pub-id pub-id-type="pmid">21747789</pub-id></element-citation></ref><ref id="CR135"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Windt</surname><given-names>GJ</given-names></name><name><surname>Everts</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name><name><surname>Curtis</surname><given-names>JD</given-names></name><name><surname>Freitas</surname><given-names>TC</given-names></name><name><surname>Amiel</surname><given-names>E</given-names></name><name><surname>Pearce</surname><given-names>EJ</given-names></name><name><surname>Pearce</surname><given-names>EL</given-names></name></person-group><article-title>Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development</article-title><source>Immunity</source><year>2012</year><volume>36</volume><issue>1</issue><fpage>68</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.12.007</pub-id><?supplied-pmid 22206904?><pub-id pub-id-type="pmid">22206904</pub-id></element-citation></ref><ref id="CR136"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>S</given-names></name><name><surname>Perera</surname><given-names>LP</given-names></name><name><surname>Terabe</surname><given-names>M</given-names></name><name><surname>Ni</surname><given-names>L</given-names></name><name><surname>Waldmann</surname><given-names>TA</given-names></name><name><surname>Berzofsky</surname><given-names>JA</given-names></name></person-group><article-title>IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis</article-title><source>Proc Natl Acad Sci U S A</source><year>2008</year><volume>105</volume><issue>13</issue><fpage>5201</fpage><lpage>5206</lpage><pub-id pub-id-type="doi">10.1073/pnas.0801003105</pub-id><?supplied-pmid 18362335?><pub-id pub-id-type="pmid">18362335</pub-id></element-citation></ref><ref id="CR137"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borch</surname><given-names>TH</given-names></name><name><surname>Donia</surname><given-names>M</given-names></name><name><surname>Andersen</surname><given-names>MH</given-names></name><name><surname>Svane</surname><given-names>IM</given-names></name></person-group><article-title>Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies</article-title><source>Drug Discov Today</source><year>2015</year><?supplied-pmid 26189934?><pub-id pub-id-type="pmid">26189934</pub-id></element-citation></ref><ref id="CR138"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gettinger</surname><given-names>SN</given-names></name><name><surname>Horn</surname><given-names>L</given-names></name><name><surname>Gandhi</surname><given-names>L</given-names></name><name><surname>Spigel</surname><given-names>DR</given-names></name><name><surname>Antonia</surname><given-names>SJ</given-names></name><name><surname>Rizvi</surname><given-names>NA</given-names></name><name><surname>Powderly</surname><given-names>JD</given-names></name><name><surname>Heist</surname><given-names>RS</given-names></name><name><surname>Carvajal</surname><given-names>RD</given-names></name><name><surname>Jackman</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer</article-title><source>J Clin Oncol</source><year>2015</year><volume>33</volume><issue>18</issue><fpage>2004</fpage><lpage>2012</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.58.3708</pub-id><?supplied-pmid 25897158?><pub-id pub-id-type="pmid">25897158</pub-id></element-citation></ref><ref id="CR139"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gros</surname><given-names>A</given-names></name><name><surname>Robbins</surname><given-names>PF</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>YF</given-names></name><name><surname>Turcotte</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>E</given-names></name><name><surname>Wunderlich</surname><given-names>JR</given-names></name><name><surname>Mixon</surname><given-names>A</given-names></name><name><surname>Farid</surname><given-names>S</given-names></name><name><surname>Dudley</surname><given-names>ME</given-names></name><etal/></person-group><article-title>PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors</article-title><source>J Clin Invest</source><year>2014</year><volume>124</volume><issue>5</issue><fpage>2246</fpage><lpage>2259</lpage><pub-id pub-id-type="doi">10.1172/JCI73639</pub-id><?supplied-pmid 24667641?><pub-id pub-id-type="pmid">24667641</pub-id></element-citation></ref><ref id="CR140"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tumeh</surname><given-names>PC</given-names></name><name><surname>Harview</surname><given-names>CL</given-names></name><name><surname>Yearley</surname><given-names>JH</given-names></name><name><surname>Shintaku</surname><given-names>IP</given-names></name><name><surname>Taylor</surname><given-names>EJ</given-names></name><name><surname>Robert</surname><given-names>L</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Spasic</surname><given-names>M</given-names></name><name><surname>Henry</surname><given-names>G</given-names></name><name><surname>Ciobanu</surname><given-names>V</given-names></name><etal/></person-group><article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title><source>Nature</source><year>2014</year><volume>515</volume><issue>7528</issue><fpage>568</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1038/nature13954</pub-id><?supplied-pmid 25428505?><pub-id pub-id-type="pmid">25428505</pub-id></element-citation></ref><ref id="CR141"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niezgoda</surname><given-names>A</given-names></name><name><surname>Niezgoda</surname><given-names>P</given-names></name><name><surname>Czajkowski</surname><given-names>R</given-names></name></person-group><article-title>Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy</article-title><source>BioMed Res Int</source><year>2015</year><volume>2015</volume><fpage>851387</fpage><pub-id pub-id-type="doi">10.1155/2015/851387</pub-id><?supplied-pmid 26171394?><pub-id pub-id-type="pmid">26171394</pub-id></element-citation></ref><ref id="CR142"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goovaerts</surname><given-names>O</given-names></name><name><surname>Jennes</surname><given-names>W</given-names></name><name><surname>Massinga-Loembe</surname><given-names>M</given-names></name><name><surname>Ceulemans</surname><given-names>A</given-names></name><name><surname>Worodria</surname><given-names>W</given-names></name><name><surname>Mayanja-Kizza</surname><given-names>H</given-names></name><name><surname>Colebunders</surname><given-names>R</given-names></name><name><surname>Kestens</surname><given-names>L</given-names></name><name><surname>Group</surname><given-names>T-IS</given-names></name></person-group><article-title>LPS-binding protein and IL-6 mark paradoxical tuberculosis immune reconstitution inflammatory syndrome in HIV patients</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>11</issue><fpage>e81856</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0081856</pub-id><?supplied-pmid 24312369?><pub-id pub-id-type="pmid">24312369</pub-id></element-citation></ref><ref id="CR143"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>JF</given-names></name><name><surname>Lu</surname><given-names>ZY</given-names></name><name><surname>Jourdan</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>B</given-names></name></person-group><article-title>Interleukin-6 as a therapeutic target</article-title><source>Clin Cancer Res</source><year>2015</year><volume>21</volume><issue>6</issue><fpage>1248</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-2291</pub-id><?supplied-pmid 25589616?><pub-id pub-id-type="pmid">25589616</pub-id></element-citation></ref><ref id="CR144"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambrechts</surname><given-names>D</given-names></name><name><surname>Lenz</surname><given-names>HJ</given-names></name><name><surname>de Haas</surname><given-names>S</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Scherer</surname><given-names>SJ</given-names></name></person-group><article-title>Markers of response for the antiangiogenic agent bevacizumab</article-title><source>J Clin Oncol</source><year>2013</year><volume>31</volume><issue>9</issue><fpage>1219</fpage><lpage>1230</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.46.2762</pub-id><?supplied-pmid 23401453?><pub-id pub-id-type="pmid">23401453</pub-id></element-citation></ref><ref id="CR145"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>L</given-names></name><name><surname>Chelluri</surname><given-names>LK</given-names></name><name><surname>Gaddam</surname><given-names>S</given-names></name></person-group><article-title>Mesenchymal Stromal Cell Therapy in MDR/XDR Tuberculosis: A Concise Review</article-title><source>Arch Immunol Ther Exp (Warsz)</source><year>2015</year></element-citation></ref><ref id="CR146"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Axelsson-Robertson</surname><given-names>R</given-names></name><name><surname>Loxton</surname><given-names>AG</given-names></name><name><surname>Walzl</surname><given-names>G</given-names></name><name><surname>Ehlers</surname><given-names>MM</given-names></name><name><surname>Kock</surname><given-names>MM</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name></person-group><article-title>A Broad Profile of Co-Dominant Epitopes Shapes the Peripheral Mycobacterium tuberculosis Specific CD8+ T-Cell Immune Response in South African Patients with Active Tuberculosis</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><issue>3</issue><fpage>e58309</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0058309</pub-id><?supplied-pmid 23555576?><pub-id pub-id-type="pmid">23555576</pub-id></element-citation></ref></